Allogene Therapeutics' stock has increased by 12% due to positive phase 2 data for a lymphoma treatment. The other mentioned companies and their stock performances appear to be unrelated to Allogene Therapeutics. Various other stocks are being discussed in terms of their potential for growth or change in leadership, but their connection to Allogene Therapeutics is not clear.